Arcus Biosciences Share Holder Equity 2017-2022 | RCUS
Arcus Biosciences share holder equity from 2017 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Arcus Biosciences Annual Share Holder Equity
(Millions of US $) |
| 2022 |
$657 |
| 2021 |
$842 |
| 2020 |
$502 |
| 2019 |
$164 |
| 2018 |
$235 |
| 2017 |
$154 |
| 2016 |
$0 |
Arcus Biosciences Quarterly Share Holder Equity
(Millions of US $) |
| 2022-12-31 |
$657 |
| 2022-09-30 |
$699 |
| 2022-06-30 |
$747 |
| 2022-03-31 |
$797 |
| 2021-12-31 |
$842 |
| 2021-09-30 |
$543 |
| 2021-06-30 |
$605 |
| 2021-03-31 |
$665 |
| 2020-12-31 |
$502 |
| 2020-09-30 |
$544 |
| 2020-06-30 |
$429 |
| 2020-03-31 |
$141 |
| 2019-12-31 |
$164 |
| 2019-09-30 |
$177 |
| 2019-06-30 |
$197 |
| 2019-03-31 |
$222 |
| 2018-12-31 |
$235 |
| 2018-09-30 |
$245 |
| 2018-06-30 |
$255 |
| 2018-03-31 |
$267 |
| 2017-12-31 |
$154 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.318B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
